Sociedad Americana de Hirudoterapia

Anticoagulation during ECMO in neonatal and paediatric patients.

Review published in Thrombosis research (2018)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewEnsayos clínicosDesarrollo de fármacosBarton et al. · Thrombosis research, 2018

Abstract

Extracorporeal Membrane Oxygenation (ECMO) is a form of Extracorporeal Life Support (ECLS) which is used frequently in the paediatric and neonatal setting to support either the pulmonary, or both the pulmonary and cardiac systems. Management of ECMO requires the use of systemic anticoagulation to prevent patient and circuit based thrombosis, which in turn increases the risk of haemorrhage. A number of coagulation tests, laboratory and point of care based, are used to monitor anticoagulation, however the evidence for correlation of the test results with level of anticoagulant and clinical outcomes in children remains poor.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsBlood Coagulation TestsChildDrug MonitoringExtracorporeal Membrane OxygenationHemorrhageHemostasisHumansInfantThrombosis

Resumen

Extracorporeal Membrane Oxygenation (ECMO) is a form of Extracorporeal Life Support (ECLS) which is used frequently in the paediatric and neonatal setting to support either the pulmonary, or both the pulmonary and cardiac systems. Management of ECMO requires the use of systemic anticoagulation to...

Por qué esto importa para la hirudoterapia

This review discussed the use of systemic anticoagulation and the challenges of monitoring its therapeutic effects during extracorporeal membrane oxygenation in pediatric and neonatal patients, noting that evidence for correlation between coagulation test results and clinical outcomes in children remains poor. The abstract addresses the clinical tension between preventing thrombosis and increasing hemorrhage risk in this critical care setting. It does not mention leeches, hirudotherapy, hirudin, or any leech-derived substances. Based solely on this abstract, there is no defensible connection to ASH's domain.

Citación

Anticoagulation during ECMO in neonatal and paediatric patients.

Barton et al. · Thrombosis research, 2018

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.